RELMADA THERAPEUTICS, INC. Proceeds from Stock Plans
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Stock Plans of $42.73 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2022-11-10
- 2022-09-30: Proceeds from Stock Plans 9 month $42.73M.
| Period end | Proceeds from Stock Plans 9 month |
|---|---|
| 2022-09-30 | $42.73M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |